FUNDING OPPORTUNITY IN GPPAD – ADVANCING THE UNDERSTANDING OF TYPE 1 DIABETES PATHOGENESIS (BIOSAMPLES PROVIDED FROM A PRIMARY PREVENTION TRIAL)
Launched in late 2017, the Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) is designed to carry out newborn screening in the general population, identify infants at high genetic risk of developing type 1 diabetes, and offer them participation in trials to prevent disease initiation.
The Primary Oral Insulin Trial (POInT) is designed to determine if administration of high dose oral insulin can prevent the initiation of type 1 diabetes-related autoimmunity in young children at high genetic risk.
They are announcing a Request For Proposals (RFP) for innovative research on biosamples from the POInT trial. The aim is to support cutting-edge analysis techniques relevant to pancreatic, metabolic, or immune research, to complement ongoing research approaches and analyses being carried out by GPPAD.
More information is available here.
Please contact the cc@gppad.org at the GPPAD Coordination Center direct with scientific and application-related questions.